While prostate cancer statistics may seem daunting, advances in detection, treatment, and active surveillance offer patients ...

U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW ...

The global market for prostate cancer market is likely to be valued at around USD 12.9 billion in 2025 and is projected to ...

U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that ...

Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...

So as way of background, EZH2 is an epigenetic enzyme that's overexpressed in castrate-resistant prostate cancer, and it's ...

A novel, rapid blood test demonstrated potential for detecting early-stage pancreatic cancer, according to results of a ...

in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1 ...

Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...

Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane ...

Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific ... EBRT and 51% for those undergoing EBRT alone. Additionally, the metastasis-free survival (MFS) rate after 15 ...